Vanguard Group Inc Acurx Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 491,687 shares of ACXP stock, worth $968,623. This represents 0.0% of its overall portfolio holdings.
Number of Shares
491,687
Previous 491,687
-0.0%
Holding current value
$968,623
Previous $1.2 Million
8.14%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ACXP
# of Institutions
30Shares Held
1.21MCall Options Held
14.3KPut Options Held
18.3K-
Prospect Financial Services LLC Melville, NY278KShares$547,8570.48% of portfolio
-
Geode Capital Management, LLC Boston, MA130KShares$256,1290.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC53.7KShares$105,8570.0% of portfolio
-
Morgan Stanley New York, NY46.4KShares$91,4090.0% of portfolio
-
State Street Corp Boston, MA43.5KShares$85,6280.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $22.8M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...